The U.S. Federal Trade Commission has issued a second request to Pfizer and Allergan for more information related to the mega-merger's antitrust probe.
The request was anticipated by both companies, and will lengthen the review of how the merger will affect competition, including looking closely at drug overlaps.
The deal is still waiting on EU regulatory approval, approval from Pfizer and Allergan shareholders, and the completion of Allergan’s pending generics divestiture to Teva Pharmaceuticals. Pfizer and Allergan still expect the deal to close in the second half of this year.
Read the Bloomberg coverage